Percentage of patients with rheumatoid arthritis achieving 20%, 50%, and 70% improvement in ACR measure (mITT population).
| Treatment Group | ACR20 | ACR50 | ACR70 | |||
|---|---|---|---|---|---|---|
| 12 wk | 16 wk | 12 wk | 16 wk | 12 wk | 16 wk | |
| MTX, n = 51 | 39.2 (CI 25.8, 53.9) | 37.3 (CI 24.1, 51.9) | 13.7 (CI 5.7, 26.3) | 13.7 (CI 5.7, 26.3) | 5.9 (CI 1.2, 16.2) | 5.9 (CI 1.2, 16.2) |
| CH-1504 0.25 mg/day, n = 48 | 43.8 (CI 29.5, 58.8) | 35.4 (CI 22.2, 50.5) | 8.3 (CI 2.3, 20.0) | 12.5 (CI 4.7, 25.2) | 2.1 (CI 0.1, 11.1) | 4.2 (CI 0.5, 14.3) |
| CH-1504 0.5 mg/day, n = 48 | 39.6 (CI 25.8, 54.7) | 41.7 (CI 27.6, 56.8) | 10.4 (CI 3.5, 22.7) | 22.9 (CI 12, 37.3) | 4.2 (CI 0.5, 14.3) | 10.4 (CI 3.5, 22.7) |
| CH-1504 1 mg/day, n = 53 | 34 (CI 21.5, 48.3) | 32.1 (CI 19.9, 46.3) | 5.7 (CI 1.2, 15.7) | 9.4 (CI 3.1, 20.7) | 0 | 3.8 (CI 0.5, 13) |
ACR: American College of Rheumatology; mITT: modified intent to treat; MTX: methotrexate.